| Peter Joseph Ninneman Iii, | |
|
21 Municipal Dr, Arnold, MO 63010-1012 | |
| (636) 296-6206 | |
| Not Available |
| Full Name | Peter Joseph Ninneman Iii |
|---|---|
| Gender | Male |
| Speciality | Counselor - Addiction (substance Use Disorder) |
| Location | 21 Municipal Dr, Arnold, Missouri |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033519673 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YA0400X | Counselor - Addiction (substance Use Disorder) | 2014009981 (Missouri) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Peter Joseph Ninneman Iii, 21 Municipal Dr, Arnold, MO 63010-1012 Ph: () - | Peter Joseph Ninneman Iii, 21 Municipal Dr, Arnold, MO 63010-1012 Ph: (636) 296-6206 |
News Archive
Massachusetts health insurers' reluctance to join a national experiment to improve care for disabled lower-income adults has forced the state to scale back the program even before it starts. Massachusetts is among the first states to roll out the national program, but half the insurers that were expected to participate backed out because they feared losing money. That will mean fewer options for patients when enrollment opens for the voluntary "One Care" program in October (Conaboy, 7/29).
SillaJen, Inc., a private, clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, has announced the initiation of a multinational randomized Phase 3 open-label study of its lead product candidate, Pexa-Vec (formerly JX-594), in patients with advanced liver cancer, also known as hepatocellular carcinoma (HCC).
"The decision by India's Supreme Court to overturn the patent on Novartis's cancer treatment Glivec is good news for more affordable health care and bad news for drug innovation," a Financial Times editorial states, adding, "It fails fundamentally to address either issue, both of which need wide-ranging reform.
Dutch vaccine development company Mucosis B.V. announced today that it has received an innovation credit line of approximately € 3 million from Agentschap NL, an agency of the Dutch Ministry of Economic Affairs. Mucosis will use this loan towards the clinical development of its lead product FluGEM™, an influenza vaccine that can be administered by a simple spray in the nose. The loan will be redeemed only if the FluGEM™ clinical development program is concluded successfully.
A new walk-through coronavirus testing facility has opened for those with symptoms to book appointments at Beach Street Car Park West (LL57 1AT) in Bangor, as part of the UK Government's UK-wide drive to continue to improve the accessibility of coronavirus testing for local communities.
› Verified 2 days ago
Lauren Lofrano, Counselor Medicare: Medicare Enrolled Practice Location: 21 Municipal Dr, Arnold, MO 63010 Phone: 636-296-6206 Fax: 636-296-0102 | |
Mrs. Christine Rothrock, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 161 Arnold Crossroads Ctr, Arnold, MO 63010 Phone: 314-660-3019 | |
Brittany Craden, LPC Counselor Medicare: Medicare Enrolled Practice Location: 21 Municipal Dr, Arnold, MO 63010 Phone: 636-931-2700 | |
Adila Zafer, PLPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 21 Municipal Dr, Arnold, MO 63010 Phone: 844-853-8937 | |
Audrey Michelle Weddington, LPC Counselor Medicare: Medicare Enrolled Practice Location: 21 Municipal Dr, Arnold, MO 63010 Phone: 844-853-8937 | |
Leigh Emmendorfer, Counselor Medicare: Not Enrolled in Medicare Practice Location: 16 Municipal Dr Ste D, Arnold, MO 63010 Phone: 636-333-2641 |